

PHARMACEUTICAL TURNOVER
Three months ended 30th June 2005

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	1,214	13	12	605	21	18	420	5	6	189	6	10
<i>Seretide/Advair</i>	725	22	21	397	34	31	259	9	10	69	12	17
<i>Flixotide/Flovent</i>	159	2	2	64	1	(2)	48	1	-	47	3	9
<i>Serevent</i>	85	(9)	(9)	26	(27)	(28)	43	1	5	16	2	-
<i>Flixonase/Flonase</i>	148	13	11	113	15	13	19	4	-	16	13	14
CENTRAL NERVOUS SYSTEM	769	(12)	(12)	471	(17)	(19)	181	(6)	(5)	117	8	9
<i>Seroxat/Paxil</i>	152	(47)	(46)	30	(80)	(79)	46	(30)	(31)	76	5	7
<i>Paxil IR</i>	126	(33)	(33)	6	(88)	(88)	46	(30)	(30)	74	5	6
<i>Paxil CR</i>	26	(73)	(73)	24	(75)	(74)	-	-	-	2	12	100
<i>Wellbutrin</i>	167	(11)	(13)	164	(12)	(14)	1	35	-	2	>100	>100
<i>Wellbutrin IR, SR</i>	13	(81)	(83)	11	(83)	(85)	1	35	-	1	>100	>100
<i>Wellbutrin XL</i>	154	34	32	153	33	32	-	-	-	1	>100	>100
<i>Imigran/Imitrex</i>	162	3	3	112	5	3	37	(1)	3	13	(1)	-
<i>Lamictal</i>	216	28	26	140	38	35	62	11	11	14	18	27
<i>Requip</i>	34	21	17	15	25	15	17	17	21	2	16	-
ANTI-VIRALS	634	7	7	305	5	3	199	9	9	130	10	12
HIV	386	6	5	187	(1)	(2)	157	11	11	42	16	17
<i>Combivir</i>	148	6	5	70	4	1	60	6	7	18	15	13
<i>Trizivir</i>	75	(13)	(14)	40	(18)	(18)	32	(5)	(6)	3	(6)	(25)
<i>Epivir</i>	68	(11)	(12)	24	(37)	(38)	33	14	14	11	17	22
<i>Ziagen</i>	36	(6)	(3)	15	(20)	(17)	16	1	7	5	23	25
<i>Retrovir</i>	10	(4)	9	4	(9)	-	4	(6)	-	2	8	(33)
<i>Agenerase, Lexiva</i>	26	72	73	16	37	33	8	>100	>100	2	46	-
<i>Epzicom/Kivexa</i>	23	>100	>100	18	-	-	4	-	-	1	-	-
Herpes	195	8	7	107	15	10	34	(3)	(3)	54	3	8
<i>Valtrex</i>	162	13	12	106	15	12	24	5	4	32	14	19
<i>Zovirax</i>	33	(11)	(11)	1	6	(50)	10	(17)	(17)	22	(10)	(4)
<i>Zeffix</i>	37	7	12	3	17	50	7	6	(40)	27	6	4
ANTI-BACTERIALS	348	(10)	(9)	55	(37)	(38)	155	(7)	(6)	138	5	8
<i>Augmentin</i>	155	(14)	(13)	29	(45)	(45)	70	(7)	(7)	56	10	12
<i>Augmentin IR</i>	129	(3)	(3)	7	(31)	(36)	67	(9)	(8)	55	11	12
<i>Augmentin ES, XR</i>	26	(44)	(59)	22	(44)	(52)	3	55	>100	1	(22)	-
<i>Zinnat/Ceftin</i>	40	(19)	(17)	1	(66)	(50)	22	(22)	(19)	17	(9)	(11)
METABOLIC	393	17	16	267	18	15	45	45	50	81	3	8
<i>Avandia, Avandamet</i>	352	16	15	263	16	13	39	55	63	50	(5)	2
<i>Boniva</i>	4	-	-	4	-	-	-	-	-	-	-	-
VACCINES	322	15	16	66	2	(1)	147	26	27	109	11	15
<i>Hepatitis</i>	116	10	10	33	(3)	(6)	62	18	22	21	11	11
<i>Infanrix/Pediarix</i>	102	18	19	32	2	-	51	34	34	19	11	19
ONCOLOGY AND EMESIS	248	6	5	184	10	7	42	(6)	(5)	22	(1)	5
<i>Zofran</i>	204	7	6	154	12	9	32	(8)	(6)	18	2	6
<i>Hycamtin</i>	23	(8)	(8)	14	(10)	(13)	7	(5)	-	2	(4)	-
CARDIOVASCULAR AND UROGENITAL	312	43	42	168	21	19	104	98	96	40	48	54
<i>Coreg</i>	125	13	11	124	13	11	-	-	-	1	(29)	-
<i>Levitra</i>	11	35	22	10	>100	>100	1	(77)	(80)	-	-	-
<i>Avodart</i>	28	>100	>100	12	70	71	14	>100	>100	2	>100	100
<i>Arixtra</i>	5	-	-	3	-	-	2	-	-	-	-	-
<i>Fraxiparine</i>	55	-	-	-	-	-	45	-	-	10	-	-
<i>Vesicare</i>	1	-	-	1	-	-	-	-	-	-	-	-
OTHER	265	7	7	16	(32)	(33)	80	8	10	169	12	12
<i>Zantac</i>	60	(15)	(14)	13	(35)	(35)	15	(23)	(17)	32	3	-
	4,505	6	6	2,137	3	(1)	1,373	9	10	995	9	12

PHARMACEUTICAL TURNOVER
Six months ended 30th June 2005

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	2,412	12	12	1,196	17	13	836	7	9	380	12	13
<i>Seretide/Advair</i>	1,415	22	20	777	29	25	510	14	15	128	11	14
<i>Flixotide/Flovent</i>	313	1	1	125	1	(2)	97	(2)	1	91	4	6
<i>Serevent</i>	164	(10)	(10)	50	(29)	(31)	83	(3)	-	31	14	15
<i>Flixonase/Flonase</i>	319	13	10	233	6	3	33	1	-	53	70	71
CENTRAL NERVOUS SYSTEM	1,527	(13)	(15)	949	(18)	(20)	365	(6)	(5)	213	(2)	(1)
<i>Seroxat/Paxil</i>	315	(45)	(45)	80	(72)	(73)	98	(29)	(29)	137	(4)	(4)
<i>Paxil IR</i>	248	(35)	(35)	17	(82)	(83)	98	(29)	(29)	133	(5)	(5)
<i>Paxil CR</i>	67	(65)	(66)	63	(67)	(67)	-	-	-	4	39	33
<i>Wellbutrin</i>	330	(18)	(20)	324	(18)	(21)	1	56	-	5	12	(17)
<i>Wellbutrin IR, SR</i>	45	(77)	(78)	41	(79)	(80)	1	56	-	3	(7)	(40)
<i>Wellbutrin XL</i>	285	43	39	283	43	39	-	-	-	2	>100	>100
<i>Imigran/Imitrex</i>	329	2	-	235	3	-	70	(3)	(1)	24	(1)	-
<i>Lamictal</i>	411	29	27	260	38	33	125	16	17	26	14	18
<i>Requip</i>	64	18	16	28	20	12	32	16	19	4	15	33
ANTI-VIRALS	1,237	8	7	606	10	7	385	4	5	246	9	10
HIV	749	6	5	365	4	1	301	6	7	83	14	15
<i>Combivir</i>	288	4	3	138	4	1	116	2	4	34	9	10
<i>Trizivir</i>	149	(10)	(11)	79	(12)	(14)	63	(8)	(7)	7	(6)	(13)
<i>Epivir</i>	134	(9)	(9)	49	(29)	(32)	63	8	9	22	18	22
<i>Ziagen</i>	69	(9)	(8)	28	(22)	(22)	30	(2)	-	11	19	22
<i>Retrovir</i>	21	2	-	8	(2)	-	8	(6)	-	5	24	-
<i>Agenerase, Lexiva</i>	48	>100	>100	30	75	67	15	>100	>100	3	73	>100
<i>Epzicom/Kivexa</i>	40	>100	>100	33	-	-	6	>100	>100	1	-	-
Herpes	392	12	10	221	23	19	70	(3)	(3)	101	2	3
<i>Valtrex</i>	326	20	17	218	25	20	49	9	9	59	12	13
<i>Zovirax</i>	66	(16)	(15)	3	(32)	(40)	21	(23)	(22)	42	(10)	(9)
<i>Zeffix</i>	66	4	5	6	12	20	11	2	10	49	3	2
ANTI-BACTERIALS	765	(5)	(5)	131	(32)	(35)	377	4	6	257	3	3
<i>Augmentin</i>	347	(9)	(9)	75	(41)	(43)	168	5	7	104	11	11
<i>Augmentin IR</i>	283	3	4	19	(23)	(27)	162	3	5	102	12	11
<i>Augmentin ES, XR</i>	64	(41)	(59)	56	(46)	(53)	6	>100	>100	2	18	-
<i>Zinnat/Ceftin</i>	102	(7)	(5)	4	(27)	(33)	64	(4)	-	34	(10)	(8)
METABOLIC	712	19	17	482	19	15	85	38	42	145	10	12
<i>Avandia, Avandamet</i>	639	20	18	478	18	14	71	54	58	90	9	13
VACCINES	570	10	10	120	2	(2)	261	18	21	189	4	6
<i>Hepatitis</i>	210	7	8	59	(7)	(9)	110	16	18	41	12	14
<i>Infanrix/Pediarix</i>	185	14	14	60	10	7	91	23	25	34	(1)	3
ONCOLOGY AND EMESIS	483	7	5	355	11	7	85	(3)	(1)	43	2	5
<i>Zofran</i>	393	8	6	293	11	7	65	(5)	(2)	35	4	6
<i>Hycamtin</i>	48	(1)	(2)	31	-	(3)	14	(2)	-	3	-	-
CARDIOVASCULAR AND UROGENITAL	622	50	48	344	32	27	207	100	>100	71	44	48
<i>Coreg</i>	260	30	26	257	31	27	-	-	-	3	(29)	(25)
<i>Levitra</i>	21	(15)	(19)	19	67	58	2	(78)	(80)	-	-	-
<i>Avodart</i>	54	>100	>100	24	88	85	26	>100	>100	4	>100	>100
<i>Arixtra</i>	9	-	-	5	-	-	4	-	-	-	-	-
<i>Fraxiparine</i>	107	-	-	-	-	-	90	-	-	17	-	-
<i>Vesicare</i>	4	-	-	4	-	-	-	-	-	-	-	-
OTHER	516	2	2	33	(26)	(28)	160	5	7	323	5	4
<i>Zantac</i>	119	(14)	(14)	26	(27)	(30)	31	(21)	(18)	62	(2)	(2)
	8,844	6	5	4,216	4	-	2,761	9	11	1,867	7	8

CONSUMER HEALTHCARE TURNOVER
Three months ended 30th June 2005

	£m	Growth CER%	£m
Over-the-counter medicines	347	3	4
Analgesics	88	5	4
Dermatological	46	(6)	(8)
Gastrointestinal	61	1	3
Respiratory tract	30	12	20
Smoking control	78	7	5
Natural wellness support	33	3	3
Oral care	232	2	3
Nutritional healthcare	162	4	5
Total	741	3	3

CONSUMER HEALTHCARE TURNOVER
Six months ended 30th June 2005

	£m	Growth CER%	£m
Over-the-counter medicines	690	4	3
Analgesics	172	4	4
Dermatological	85	(7)	(8)
Gastrointestinal	119	1	1
Respiratory tract	68	12	15
Smoking control	161	12	10
Natural wellness support	66	(1)	-
Oral care	451	-	1
Nutritional healthcare	297	3	2
Total	1,438	3	2

INCOME STATEMENT
Three months ended 30th June 2005

	Q2 2005 Statutory £m	Q2 2004		£%
		Statutory (restated) £m	Growth* CER%	
Turnover:				
Pharmaceuticals	4,505	4,255	6	6
Consumer Healthcare	741	716	3	3
TURNOVER	5,246	4,971	6	6
Cost of sales	(1,155)	(1,044)	10	11
Gross profit	4,091	3,927	4	4
Selling, general and administration	(1,681)	(1,783)	(6)	6
Research and development	(702)	(696)	1	1
Other operating income	3	77		
Operating profit:				
Pharmaceuticals	1,540	1,380	13	12
Consumer Healthcare	171	145	16	18
OPERATING PROFIT	1,711	1,525	13	12
Finance income	56	54		
Finance expense	(115)	(100)		
Share of after tax profits of joint ventures and associates	10	16		
Profit on disposal of interest in associates	-	45		
PROFIT BEFORE TAXATION	1,662	1,540	9	8
Taxation	(473)	(426)		
<i>Tax rate %</i>	28.5%	27.7%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,189	1,114	8	7
Profit attributable to minority interests	31	25		
Profit attributable to shareholders	1,158	1,089	8	6
EARNINGS PER SHARE	20.4p	18.9p	10	8
Diluted earnings per share	20.2p	18.9p		

INCOME STATEMENT
Six months ended 30th June 2005

	Q2 2005 Statutory £m	Q2 2004		£%
		Statutory (restated) £m	Growth* CER%	
Turnover:				
Pharmaceuticals	8,844	8,423	6	5
Consumer Healthcare	1,438	1,403	3	2
TURNOVER	10,282	9,826	5	5
Cost of sales	(2,282)	(2,079)	10	10
Gross profit	8,000	7,747	4	3
Selling, general and administration	(3,326)	(3,508)	(4)	(5)
Research and development	(1,365)	(1,355)	2	1
Other operating income	149	134		
Operating profit:				
Pharmaceuticals	3,166	2,775	16	14
Consumer Healthcare	292	243	19	20
OPERATING PROFIT	3,458	3,018	16	15
Finance income	105	97		
Finance expense	(213)	(184)		
Share of after tax profits of joint ventures and associates	23	30		
Profit on disposal of interest in associates	-	45		
PROFIT BEFORE TAXATION	3,373	3,006	13	12
Taxation	(961)	(832)		
<i>Tax rate %</i>	28.5%	27.7%		
PROFIT AFTER TAXATION FOR THE PERIOD	2,412	2,174	12	11
Profit attributable to minority interests	52	48		
Profit attributable to shareholders	2,360	2,126	12	11
EARNINGS PER SHARE	41.5p	36.9p	14	12
Diluted earnings per share	41.2p	36.9p		